![]() ![]() Those trails will be forthcoming.” He then adds, “Testing for mutations will be the future of preventive medicine in oncology.” Kashif Ali, a board certified hematologist-oncologist that practices in Maryland, states, “Currently, we have not adopted guidelines in pre-emptive treatment based on just mutations. ![]() Theoretically, select patients could receive this test even before the onset of symptoms and if they test positively, could be identified and treated so they never experience the burden of cancer symptoms and treatment.ĭr. In this way, treatment can be personalized and tailored to the individual patient.Īlthough not currently FDA approved for Leukemia diagnosis, Lena Q51® could also have applications for preventive medicine. In the case of leukemia, the more mutations that are known or can be identified that are associated with the cancer, the more likely patients can be given the appropriate treatment to prolong life. The more information that is known about a disease, the more effective treatment and prevention plans can be implemented by physicians. This critical information can help guide therapy, as oncologists may recommend chemotherapy instead of bone marrow transplantation or a combination of both. Similarly, patients with the gene mutations known as NPM1 and CEBP⍺ often have a better chance of recovery than those without these mutations. Knowing that a patient has this specific mutation can affect their overall prognosis, as doctors can offer these patients a bone marrow transplant that can eventually prolong their lives. As an example, patients that test positive for the FLT3 mutation often have a high risk of recurrence following treatment. Identifying various gene mutations in leukemia remains crucial in understanding the prognosis and even the treatment for the various types of leukemia. ![]() Lena Q51® is able to provide results in less than four hours, whereas most other molecular tests and bone marrow biopsy tests require days before results are found. This innovative test utilizes highly multiplex quantitative PCR (Polymerase Chain Reaction), which is a laboratory technique that amplifies DNA, or genetic material necessary to identify various mutations. The objective is to analyze the genetic landscape of multiple fusion genes in patients. introduced Lena Q51, a groundbreaking Leukemia diagnostic test capable of detecting up to 51 gene mutations in a single patient. In January of this year, Scheer and Alercell Inc. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |